Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04192370 · ClinicalTrials.gov registry record · Phase 2
Cannabidiol Use to Reduce Cravings in Individuals With Opioid Use Disorder on Buprenorphine
A Phase 2 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT04192370 is a Phase 2 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 8 participants.
The verdict
NCT04192370, a Phase 2 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this week-long study is to determine the impact of cannabidiol on cue-induced cravings among individuals with opioid use disorder who are stable on sublingual buprenorphine treatment.
Interventions
- DRUG Cannabidiol 600mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-08-03 |
| Est. Completion | 2021-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04192370
The ClinicalTrials.gov registry entry for NCT04192370 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cannabidiol 600mg is the first listed.
NCT04192370 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04192370 about?
NCT04192370 is a clinical study titled "Cannabidiol Use to Reduce Cravings in Individuals With Opioid Use Disorder on Buprenorphine". The purpose of this week-long study is to determine the impact of cannabidiol on cue-induced cravings among individuals with opioid use disorder who are stable on sublingual buprenorphine treatment.
What is the current status of trial NCT04192370?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2020-08-03. Estimated completion is 2021-12-30.
What interventions are being tested in trial NCT04192370?
The interventions under investigation include: Cannabidiol 600mg (DRUG).
Who is sponsoring clinical trial NCT04192370?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.